Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Must Reads In FDA Actions

FDA Actions for November/December 2018

FDA Approves Hyrimoz for Plaque Psoriasis, Sandoz news release; 2018 Oct 31

More must reads

FDA Actions for September/October 2018

FDA Approves Seysara for Severe Acne Vulgaris, Paratek Pharmaceuticals, Inc. news release; 2018 Oct 2

FDA Approves Nuzyra for Acute Skin Infections, Paratek Pharmaceuticals, Inc. news release; 2018 Oct 2

Psoriasis Treatment Receives Tentative FDA Approval, Bausch Heath news release; 2018 Oct 8

FDA Approves Libtayo for Metastatic cSCC, Sanofi news release; 2018 Sep 28

More must reads

FDA Actions for July/August 2018

FDA Approves Qbrexza for Excessive Armpit Sweating, Dermira Inc. news release; 2018 Jun 29

FDA Approves Drug Combination for Melanoma, Array BioPharma news release; 2018 Jun 27

More must reads

FDA Actions for May/June 2018

FDA Approves Rituxan for Pemphigus Vulgaris, Genentech Web site; 2018 Jun 7

FDA Extends Label for Cimzia for Plaque Psoriasis, UCB news release; 2018 May 29

FDA Updates Label for Taltz for Genital Psoriasis, PharmaLive news release; 2018 May 22

FDA Approves Restylane Lyft for Back of Hands, FirstWord Pharma news release; 2018 May 21

FDA Approves Tafinlar-Mekinist Combo for Melanoma, Novartis news release; 2018 Apr 30

More must reads

FDA Actions for March/April 2018

FDA Approves Ilumya for Plaque Psoriasis, Sun Pharmaceutical Industries Ltd. news release; 2018 Mar

More must reads

Pages